株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

呼吸器疾患用吸入器の世界市場 (2018-2028年):ドライパウダー吸入器 (DPI)、単回投与型DPI、複数回投与型DPI、定量噴霧式吸入器 (MDI)、ネブライザー、ジェット式ネブライザー、超音波ネブライザー、振動型メッシュネブライザー、喘息、COPDなど

The Global Respiratory Inhalers Market 2018-2028: Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others

発行 Visiongain Ltd 商品コード 499466
出版日 ページ情報 英文 165 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=143.55円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
呼吸器疾患用吸入器の世界市場 (2018-2028年):ドライパウダー吸入器 (DPI)、単回投与型DPI、複数回投与型DPI、定量噴霧式吸入器 (MDI)、ネブライザー、ジェット式ネブライザー、超音波ネブライザー、振動型メッシュネブライザー、喘息、COPDなど The Global Respiratory Inhalers Market 2018-2028: Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others
出版日: 2018年10月24日 ページ情報: 英文 165 Pages
概要

世界の呼吸器疾患用吸入器の市場規模は、2017年には330億米ドル、2023年には380億米ドルに達する見通しです。そのうちの58%を喘息向け需要が占めています。

当レポートでは、世界の呼吸器疾患用吸入器の市場を調査し、市場および製品の定義と概要、呼吸器系疾患 (喘息・COPD) と治療の概要、主な薬剤クラス、収益規模の推移と予測、製品種類・適応症・主要国別の詳細分析、市場の促進・抑制要因や市場機会の分析、主要企業のプロファイル、将来の展望などをまとめています。

第1章 分析概要

第2章 イントロダクション:呼吸器系疾患と治療法

  • 呼吸器系疾患:概略
    • 呼吸器系疾患の分類
    • 喘息
    • 慢性閉塞性肺疾患 (COPD)
      • 有病率の動向
      • 病態生理
      • 症状
      • 治療法
      • 治療ガイドライン
      • 薬剤治療
  • 喘息・COPDの主な薬剤クラス
    • 気管支拡張剤
      • β2作動薬
      • 抗コリン (作用) 薬
      • 抗炎症薬
      • コルチコステロイド剤
      • ロイコトリエン受容体拮抗薬
      • モノクローナル抗体
      • 配合剤
    • 治験フェース (相)
    • 医療機器の関連規制 (米国・欧州)

第3章 呼吸器疾患用吸入器:世界市場の予測

  • 呼吸器疾患用吸入器市場:最新情勢
  • 主要製品
  • 主要企業
  • 呼吸器疾患用吸入器市場:主な傾向と動静

第4章 市場予測:製品種類別

  • 定量噴霧式吸入器 (MDI):市場予測 (今後11年間分)
  • ドライパウダー吸入器 (DPI):市場予測 (今後11年間分)
    • 単回投与型DPI
    • 複数回投与型DPI
  • ネブライザー:市場予測 (今後11年間分)
    • ジェット/コンプレッサー式ネブライザー
    • 超音波ネブライザー
    • 振動型メッシュネブライザー

第5章 市場予測:症状別

  • 喘息:市場予測 (今後11年間分)
  • 慢性閉塞性肺疾患 (COPD):市場予測 (今後11年間分)
  • その他の呼吸器系疾患:市場予測 (今後11年間分)

第6章 主要国市場:将来予測

  • 世界市場:地域別の内訳
  • 世界の呼吸器疾患用吸入器市場:将来予測 (今後11年間分)
    • 地域別市場シェア:変化の見通し
  • 米国市場
    • 将来予測 (今後11年間分)
    • 市場の傾向と動静
  • 欧州主要5ヶ国 (EU5) 市場
    • ドイツ市場:将来予測 (今後11年間分)
    • フランス市場:将来予測 (今後11年間分)
    • イタリア市場:将来予測 (今後11年間分)
    • スペイン市場:将来予測 (今後11年間分)
    • 英国市場:将来予測 (今後11年間分)
    • 各国市場の傾向と動静
  • 日本市場:将来予測 (今後11年間分)
  • BRIC市場
    • 中国市場:将来予測 (今後11年間分)
    • インド市場:将来予測 (今後11年間分)
    • ブラジル市場:将来予測 (今後11年間分)
    • ロシア市場:将来予測 (今後11年間分)
  • メキシコ市場:将来予測 (今後11年間分)
  • カナダ市場:将来予測 (今後11年間分)

第7章 呼吸器疾患用吸入器市場の主要企業

  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Boehringer Ingelheim
  • Merck & Co. (Merck)
  • Teva
  • Novartis International AG
  • Chiesi Farmaceutici S.p.A.
    • 製品ポートフォリオ
    • 主な財務指標
    • 昨今の主な動き (国別動向、製品パイプライン、資本取引など)

第8章 呼吸器疾患用吸入器市場の定性分析

  • 市場のダイナミクス
    • 市場促進要因、市場機会
      • 呼吸器疾患による社会的負荷の増大
      • スマート吸入器の巨大な成長機会
      • COPD向け三種薬剤併用療法:新たな収益源
    • 市場抑制要因、課題
      • 特許満了とジェネリック医薬品との競合
      • 費用感度の高い市場:高コスト性がDPIの成長率を抑制
  • ポーターのファイブフォース分析
    • 企業間競争
    • 新規参入企業の脅威
    • サプライヤーの交渉力
    • バイヤーの交渉力
    • 代替製品の脅威

第9章 結論

図表

List of Figures

  • Figure 1.1: Ageing Population Estimates 2010 - 2050
  • Figure 1.2: Global Respiratory Inhalers: Market Segmentation
  • Figure 2.1: Summary of GINA Guidance for Asthma Treatment, 2016
  • Figure 2.2: Summary of GOLD Guidance for COPD Treatment
  • Figure 3.1: World Respiratory Inhalers Market: Market Shares (%) for Major National Markets
  • Figure 3.2: Top 5 Respiratory Inhalers: Market Shares (%), 2016
  • Figure 4.1: Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2028
  • Figure 4.2: Metered Dose Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 4.3: World Dry Powder Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2028
  • Figure 4.4: Single-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 4.5: Multi-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 4.6: World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Figure 4.7: World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Figure 4.8: World Vibrating-Mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Figure 5.1: World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Disease Indication, 2016-2028
  • Figure 5.2: World Asthma Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 5.3: World COPD Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 5.4: World Respiratory Inhalers Market for Other Diseases, Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.1: Respiratory Inhalers Market: Revenues ($m) by Region, 2018
  • Figure 6.2: World Respiratory Inhalers Market: Market Shares (%) by Region, 2018
  • Figure 6.3: World Respiratory Inhalers Market Forecast: Revenues ($m) by Region, 2016-2028
  • Figure 6.4: World Respiratory Inhalers Market: Market Shares (%) by Region, 2018
  • Figure 6.5: World Respiratory Inhalers Market: Market Shares (%) by Region, 2023
  • Figure 6.6: World Respiratory Inhalers Market: Market Shares (%) by Region, 2028
  • Figure 6.7: US Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.8: EU5 Respiratory Inhalers Market Forecast: Revenues ($m) by National Market, 2016-2028
  • Figure 6.9: German Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.10: French Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.11: UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%), 2016-2028
  • Figure 6.12: Italian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.13: Spanish Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.14: Japanese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.15: BRIC Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.16: Chinese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.17: Indian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.18: Brazilian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.19: Russian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.20: Mexican Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 6.21: Canadian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2028
  • Figure 7.1: GSK: Major Respiratory Inhalers Revenue ($m), 2017
  • Figure 7.2: GSK: Major Respiratory Inhalers Revenue Share (%) by Product, 2017
  • Figure 7.3: GSK: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
  • Figure 7.4: AstraZeneca: Major Respiratory Inhalers Revenue ($m), 2017
  • Figure 7.5: AstraZeneca: Major Respiratory Inhalers Revenue Share (%), by Product, 2017
  • Figure 7.6: AstraZeneca: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
  • Figure 7.7: Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), 2017
  • Figure 7.8: Boehringer Ingelheim: Major Respiratory Inhalers Revenue Share (%), by Product, 2017
  • Figure 7.9: Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
  • Figure 7.10: Merck: Major Respiratory Inhalers Revenue ($m), 2017
  • Figure 7.11: Merck: Major Respiratory Inhalers Revenue Share (%) by Product, 2017
  • Figure 7.12: Merck: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
  • Figure 7.13: Teva: Major Respiratory Inhalers Revenue ($m), 2017
  • Figure 7.14: Teva: Major Respiratory Inhalers Revenue Share (%) by Product, 2017
  • Figure 7.15: Teva: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
  • Figure 7.16: Novartis: Major Respiratory Inhalers Revenue ($m), 2017
  • Figure 7.17: Novartis: Major Respiratory Inhalers Revenue Share (%), by Product, 2017
  • Figure 7.18: Novartis: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2028
  • Figure 7.19: Chiesi: Foster Inhaler Revenue ($m) and AGR (%), 2016-2028
  • Figure 8.1: Porter's Five Forces Analysis of the Respiratory Inhalers Market, 2016-2028
  • Figure 9.1: Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2028

List of Tables

  • Table 2.1: Classification of Respiratory Diseases
  • Table 2.2: Clinical Trial Phases
  • Table 3.1: Top 5 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2017
  • Table 4.1: World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Product Type, 2016-2028
  • Table 4.2: World Metered Dose Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.3: World Dry Powder Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Product Type, 2016-2028
  • Table 4.4: Types of Marketed Breezhaler Devices
  • Table 4.5: Single-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.6: Multi-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.7: World Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Type, 2016-2028
  • Table 4.8: World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.9: World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 4.10: World Vibrating-Mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.1: World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Disease Indication, 2016-2028
  • Table 5.2: World Asthma Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.3: World COPD Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 5.4: World Respiratory Inhalers Market for Other Diseases, Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.1: World Respiratory Inhalers Market: Revenues ($m) and Market Shares (%) by Region, 2018
  • Table 6.2: World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2016-2028
  • Table 6.3: Market Shares (%) of Leading Regional Respiratory Inhalers Markets, 2016, 2022 and 2027
  • Table 6.4: US Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.5: EU5 Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2028
  • Table 6.6: German Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.7: French Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.8: UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.9: Italian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.10: Spanish Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.11: Japanese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.12: BRIC Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.13: Chinese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.14: Indian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.15: Brazilian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.16: Russian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.17: Mexican Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 6.18: Canadian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2028
  • Table 7.1: GSK: Overview, 2017
  • Table 7.2: GSK: Respiratory Inhaler Products
  • Table 7.3: GSK: Major Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type,2016-2028
  • Table 7.4: GSK: Respiratory Therapies Pipeline, 2017
  • Table 7.5: AstraZeneca: Overview, 2017
  • Table 7.6: AstraZeneca: Respiratory Inhaler Products
  • Table 7.7: AstraZeneca: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2028
  • Table 7.8: AstraZeneca: Respiratory Therapies Pipeline, 2017
  • Table 7.9: Boehringer Ingelheim: Overview, 2017
  • Table 7.10: Boehringer Ingelheim: Respiratory Inhaler Products
  • Table 7.11: Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2028
  • Table 7.12: Merck: Overview, 2017
  • Table 7.13: Merck: Respiratory Inhaler Products
  • Table 7.14: Merck: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028
  • Table 7.15: Teva: Overview, 2017
  • Table 7.16: Teva: Respiratory Inhaler Products
  • Table 7.17: Teva: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028
  • Table 7.18: Teva: Respiratory Product Pipeline,2017
  • Table 7.19: Novartis: Overview, 2017
  • Table 7.20: Novartis: Respiratory Inhaler Products
  • Table 7.21: Novartis: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028
  • Table 7.22: Novartis: Respiratory Product Pipeline, 2016
  • Table 7.23: Chiesi: Overview, 2017
  • Table 7.24: Chiesi: Respiratory Inhaler Products
  • Table 7.25: Chiesi: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2028
  • Table 9.1: Top 10 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2017

COMPANIES LISTED:

  • 3M Drug Delivery Systems
  • Actavis
  • Adherium Limited
  • Aerogen
  • Agilent Technology
  • Airssential
  • Allied Healthcare
  • Almirall
  • Astrazeneca
  • Boehringer Ingelheim
  • Briggs Healthcare
  • CareFusion
  • Chiesi
  • Circassia Pharmaceuticals plc
  • Cipla
  • Clement Clarke International
  • Cohero Health
  • DeVilbiss Healthcare
  • Fexicare
  • Gecko Health Innovations
  • GF Health Products
  • GlaxoSmithKline
  • Heyer Medical
  • Hikma
  • IBM Watson Health
  • Innovate Biomed
  • Innoviva
  • Inspiro Medical
  • Mabis Healthcare
  • Medline Surgical
  • Merck
  • MRK Healthcare
  • Mylan
  • Nexus 6
  • Nouvag AG
  • Novartis
  • Omron Healthcare
  • Opko Health
  • Orion Pharma
  • PARI Medical
  • Pfizer
  • Philips Respironics
  • Propeller Health
  • Qualcomm Incorporated
  • Roche
  • Schering-Plough
  • Sunovion Pharma
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals
  • Theravance
  • Vectura
  • Viatris

List of Organizations Mentioned in the Report:

  • British Lung Foundation
  • Centers for Disease Control and Prevention
  • Centre for Devices and Radiological Health
  • European Databank on Medical Devices
  • European Medicines Agency
  • European Respiratory Society
  • Food and Drug Administration
  • German Ministry of Health
  • Global Initiative for Asthma
  • Global Initiative for Chronic Obstructive Lung Disease
  • IBM Watson Health
  • Kaohsiung Medical University
  • Ministry of Health, Labour and Welfare
  • Mount Sinai Hospital
  • MRC Technology
  • ServicioSanitarioNazionale
  • UK NHS
  • US National Heart, Lung, and Blood Institute
  • US National Institutes of Health
  • Weill Cornell Medicine
  • World Health Organization (WHO)
目次
Product Code: PHA0337

The global respiratory inhalers market reached $33bn in 2017 and is estimated to reach $38bn by 2023. In 2017, the asthma segment held 58% of the global respiratory inhalers market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 165-page report you will receive 121 charts- all unavailable elsewhere.

The 165-page report provides clear detailed insight into the respiratory inhalers market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Respiratory Inhalers Market from 2018-2028

Forecast of the Global Respiratory Inhalers market by Type of Product:

  • Metered Dose Inhalers (MDIs)
  • Dry Powder Inhalers (DPIs): Single-dose DPIs, Multi-dose DPIs
  • Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers

Forecast of the Global Respiratory Inhalers market by Indication:

  • Asthma
  • COPD
  • Other Respiratory Diseases

This report provides individual revenue forecasts to 2028 for these national markets:

  • The US
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Japan
  • China
  • India
  • Russia
  • Brazil
  • Mexico
  • Canada

Our study discusses the selected leading companies that are the major players in the respiratory inhalers market:

  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • GlaxoSmithKline (GSK)
  • Merck & Co.
  • Novartis
  • Teva

This report discusses factors that drive and restrain this market. As well as opportunities and challenges faced by this market.

This report discusses the Porter's Five Forces Analysis of the respiratory inhalers market.

Visiongain's study is intended for anyone requiring commercial analyses for the respiratory inhalers market. You find data, trends and predictions.

Buy our report today The Global Respiratory Inhalers Market 2018-2028: Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Respiratory Inhalers Market Overview
  • 1.2. Global Respiratory Inhalers Market Segmentation
  • 1.3. Overview of Findings
  • 1.4. Structure of the Report
  • 1.5. Why You Should Read This Report
  • 1.6. How This Report Delivers
  • 1.7. Key Questions Answered by This Analytical Report
  • 1.8. Who is This Report For?
  • 1.9. Methodology
    • 1.9.1. Primary Research
    • 1.9.2. Secondary Research
    • 1.9.3. Market Evaluation & Forecasting Methodology
  • 1.10. Frequently Asked Questions (FAQ)
  • 1.11. Associated Visiongain Reports
  • 1.12. About Visiongain

2. Introduction to Respiratory Disorders and Therapies

  • 2.1. An Introduction to Respiratory Disorders
    • 2.1.1. Classification of Respiratory Disorders
    • 2.1.2. Asthma
      • 2.1.2.1. Trends in Asthma Prevalence
      • 2.1.2.2. Pathophysiology of Asthma
      • 2.1.2.3. Symptoms of Asthma
      • 2.1.2.4. Treatment of Asthma
      • 2.1.2.5. Guidelines for Asthma Treatment
      • 2.1.2.6. Drug Treatments for Asthma
    • 2.1.3. Chronic Obstructive Pulmonary Disease (COPD)
      • 2.1.3.1. Trends in COPD Prevalence
      • 2.1.3.2. Pathophysiology of COPD
      • 2.1.3.3. Symptoms of COPD
      • 2.1.3.4. Treatment of COPD
      • 2.1.3.5. Drug Treatments for COPD
      • 2.1.3.6. Guidelines for COPD Treatment
  • 2.2. Major Drug Classes in the Treatment of Asthma and COPD
    • 2.2.1. Bronchodilators
      • 2.2.1.1. Beta2-Agonists
      • 2.2.1.2. Anticholinergics
      • 2.2.1.3. Anti-Inflammatory Drugs
      • 2.2.1.4. Corticosteroids
      • 2.2.1.5. Leukotriene Receptor Antagonists
      • 2.2.1.6. Monoclonal Antibodies in the Treatment of Respiratory Disease
      • 2.2.1.7. Combination Drugs
    • 2.2.2. Phases of Clinical Trials
    • 2.2.3. Regulation of Medical Devices
      • 2.2.3.1. The US Approval and Regulation System
      • 2.2.3.2. The EU Approval and Regulation System
      • 2.2.3.3. Post-Marketing Surveillance in the EU

3. Respiratory Inhalers: Global Market Forecast 2018-2028

  • 3.1. The Global Respiratory Inhalers Market in 2018
  • 3.2. Leading Respiratory Inhaler Products
  • 3.3. Leading Companies in the Respiratory Inhalers Market
  • 3.4. Respiratory Inhalers: Trends and Developments
    • 3.4.1. FDA Requires Replacement of CFC Inhalers with HFA Inhalers
    • 3.4.2. The WISDOM Trial: Will Steroids Lose Their Role in COPD?
    • 3.4.3. Telehealth: A Promising Market Trend
    • 3.4.4. Lifecycle Management Strategies to Counter Patent Expiry
    • 3.4.5. Advanced Inhaler Technologies to Counter Generic Erosion

4. Respiratory Inhalers Market by Product Type: Forecast 2018-2028

  • 4.1. Metered Dose Inhalers: Market Forecast 2018-2028
  • 4.2. Dry Powder Inhalers: Market Forecast 2018-2028
    • 4.2.1. Single-Dose DPIs: Market Forecast 2018-2028
    • 4.2.2. Multi-Dose DPIs: Market Forecast 2018-2028
  • 4.3. Nebulizers: Market Forecast 2018-2028
    • 4.3.1. Jet/Compressor Nebulizers: Market Forecast 2018-2028
    • 4.3.2. Ultrasonic Nebulizers: Market Forecast 2018-2028
    • 4.3.3. Vibrating-Mesh Nebulizers: Market Forecast 2018-2028

5. Respiratory Inhalers Market by Indication: Forecast 2018-2028

  • 5.1. Asthma: Market Forecast 2018-2028
  • 5.2. COPD: Market Forecast 2018-2028
  • 5.3. Other Respiratory Diseases: Market Forecast 2018-2028

6. Leading National Markets: Forecast 2018-2028

  • 6.1. Regional Breakdown of the Global Respiratory Inhalers Market
  • 6.2. World Respiratory Inhalers Market Forecast 2018-2028
    • 6.2.1. How will Regional Market Shares Change to 2027?
  • 6.3. The US Respiratory Inhalers Market 2018-2028
    • 6.3.1. The US Respiratory Inhalers Market Forecast 2018-2028
    • 6.3.2. US Respiratory Inhalers Market: Trends and Developments
  • 6.4. EU5. Respiratory Inhalers Market 2018-2028
    • 6.4.1. German Respiratory Inhalers Market Forecast 2018-2028
    • 6.4.2. French Respiratory Inhalers Market Forecast 2018-2028
    • 6.4.3. UK Respiratory Inhalers Market Forecast 2018-2028
    • 6.4.4. Italian Respiratory Inhalers Market Forecast 2018-2028
    • 6.4.5. Spanish Respiratory Inhalers Market Forecast 2018-2028
    • 6.4.6. EU5. Respiratory Inhalers Market: Trends and Developments
      • 6.4.6.1. Germany: Reform of AMNOG Pharmaceutical Rebate Law
      • 6.4.6.2. France: Social Security Finance Bill 2015
      • 6.4.6.3. UK: Improving Asthma and COPD Patient Outcomes
      • 6.4.6.4. Italy: Austerity Measures Limiting Growth
      • 6.4.6.5. Spain: The Start of Recovery in the Spanish Economy
  • 6.5. Japanese Respiratory Inhalers Market 2018-2028
  • 6.6. BRIC Respiratory Inhalers Market 2018-2028
    • 6.6.1. Chinese Respiratory Inhalers Market Forecast 2018-2028
    • 6.6.2. Indian Respiratory Inhalers Market Forecast 2018-2028
    • 6.6.3. Brazilian Respiratory Inhalers Market Forecast 2018-2028
    • 6.6.4. Russian Respiratory Inhalers Market Forecast 2018-2028
  • 6.7. Mexican Respiratory Inhalers Market Forecast 2018-2028
  • 6.8. Canadian Respiratory Inhalers Market Forecast 2018-2028

7. Leading Companies in the Respiratory Inhalers Market

  • 7.1. GlaxoSmithKline (GSK)
    • 7.1.1. GSK: Product Portfolio
    • 7.1.2. GSK: Financial Overview
    • 7.1.3. Recent Developments
      • 7.1.3.1. US FDA Approval for Labelling changes
      • 7.1.3.2. Japanese Regulatory Approval for Relvar Ellipta
      • 7.1.3.3. FDA and Japan Filing of Triple Drug Therapy
      • 7.1.3.4. FDA Approval for Breo Ellipta to Adult Asthma Patients
      • 7.1.3.5. Launch of Combination Drugs
      • 7.1.3.6. GSK Presented Data on Eosinophil Levels and COPD
      • 7.1.3.7. Approval for Arnuity Ellipta
      • 7.1.3.8. Approval for Incruse Ellipta
      • 7.1.3.9. GSK: Products in Development
  • 7.2. AstraZeneca
    • 7.2.1. AstraZeneca: Product Portfolio
    • 7.2.2. AstraZeneca: Financial Overview
    • 7.2.3. Recent Developments
      • 7.2.3.1. Japan Approval for Fasenra (benralizumab)
      • 7.2.3.2. EU Approval for Fasenra (benralizumab)
      • 7.2.3.3. FDA Approval for Fasenra (benralizumab)
      • 7.2.3.4. AstraZeneca and Circassia enter strategic collaboration
      • 7.2.3.5. FDA Approval for Symbicort in Paediatric Patients
      • 7.2.3.6. Charity-Industry Collaboration
      • 7.2.3.7. FDA approval for Bevespi Aerosphere
      • 7.2.3.8. AstraZeneca Acquired Right to Actavis' Branded Respiratory Portfolio in US and Canada
      • 7.2.3.9. AstraZeneca Acquired Almirall's Respiratory Portfolio
      • 7.2.3.10. Takeda Respiratory Portfolio Acquisition
    • 7.2.4. AstraZeneca: Products in Development
  • 7.3. Boehringer Ingelheim
    • 7.3.1. Boehringer Ingelheim: Product Portfolio
    • 7.3.2. Boehringer Ingelheim: Financial Overview
    • 7.3.3. Recent Developments
      • 7.3.3.1. Expanded indication for SPIRIVA Respimat in EU
      • 7.3.3.2. Collaboration with Kaohsiung Medical University
      • 7.3.3.3. Collaboration with Weill Cornell Medicine
      • 7.3.3.4. Collaboration with Qualcomm Incorporated
      • 7.3.3.5. Partnership with Propeller Health
      • 7.3.3.6. FDA Approval for Spiriva Respimat
      • 7.3.3.7. Regulatory Approval for Stiolto Respimat
      • 7.3.3.8. Expansion of Respimat Manufacturing Capacity
      • 7.3.3.9. FDA Approval for Stiverdi Respimat
    • 7.3.4. Boehringer Ingelheim: Respiratory Product Pipeline
  • 7.4. Merck & Co. (Merck)
    • 7.4.1. Merck: Product Portfolio
    • 7.4.2. Merck: Financial Overview
    • 7.4.3. Recent Developments
    • 7.4.4. Merck: Products in Development
  • 7.5. Teva
    • 7.5.1. Teva: Product Portfolio
    • 7.5.2. Teva: Financial Overview
    • 7.5.3. Teva: Recent Developments
      • 7.5.3.1. US launch of QVAR REDIHALER
      • 7.5.3.2. FDA Approval for RespiClick
      • 7.5.3.3. European Approval for Aerivio Spiromax
      • 7.5.3.4. FDA Approval for ProAir RespiClick (albuterol sulfate)
      • 7.5.3.5. Acquisition of Gecko Health Innovations
      • 7.5.3.6. Partnership with IBM Watson Health
    • 7.5.4. Teva: Products in Development
  • 7.6. Novartis International AG
    • 7.6.1. Novartis: Product Portfolio
    • 7.6.2. Novartis: Financial Overview
    • 7.6.3. Novartis: Recent Developments
      • 7.6.3.1. Partnership with Propeller Health
      • 7.6.3.2. Exclusive License Agreement with Sunovion Pharma
      • 7.6.3.3. Partnership with Qualcomm Incorporated
      • 7.6.3.4. FDA Approval for Utibron Neohaler
      • 7.6.3.5. Novartis Presented Data on Ultibro and Seebri
      • 7.6.3.6. Pfizer Promotes Two Novartis COPD drugs in the UK
    • 7.6.4. Novartis: Products Under Development
  • 7.7. Chiesi Farmaceutici S.p.A.
    • 7.7.1. Chiesi: Product Portfolio
    • 7.7.2. Chiesi: Financial Overview
    • 7.7.3. Chiesi: Recent Developments
      • 7.7.3.1. Approvals for Trimbow
      • 7.7.3.2. Regulatory Approval for NEXThaler
      • 7.7.3.3. Chiesi: Products Under Development

8. Qualitative Analysis of Respiratory Inhalers Market

  • 8.1. Market Dynamics
    • 8.1.1. Drivers and Opportunities
      • 8.1.1.1. Growing Burden of Respiratory Diseases
      • 8.1.1.2. Smart Inhalers Provide High Growth Opportunities
      • 8.1.1.3. Triple Drug Therapy for COPD To Offer New Revenue Prospects
    • 8.1.2. Restraints and Challenges
      • 8.1.2.1. Patent Expiry and Generic Competition
      • 8.1.2.2. High Cost Impeding Growth of DPIs In Cost-Sensitive Markets
  • 8.2. Porter's Five Forces Analysis of the Respiratory Inhalers Market
    • 8.2.1. Rivalry among Competitors [Medium]
    • 8.2.2. Threat of New Entrants [Medium]
    • 8.2.3. Power of Suppliers [Medium]
    • 8.2.4. Power of Buyers [High]
    • 8.2.5. Threat of Substitutes [Low]

9. Conclusions

  • 9.1. Respiratory Inhalers: A Maturing Market
  • 9.2. The Global Respiratory Inhalers Market, 2016-2028
  • 9.3. Leading Respiratory Inhalers
  • 9.4. Leading Respiratory Inhaler Companies
  • 9.5. Leading Regional and National Markets
  • 9.6. Global Respiratory Inhalers Market Forecast, 2018-2028
  • 9.7. The Future of Respiratory Inhalers Market
  • Appendices
  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form
Back to Top